文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多西环素暴露后预防降低MSM细菌性性传播感染

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
PubMed 文献 · Lancet Infect Dis · 2017-12-08

本研究为ANRS IPERGAY试验的开放标签随机子研究,纳入232名使用HIV暴露前预防、发生无套性行为的MSM,比较性行为后24小时内单次口服200mg多西环素与不预防的效果。10个月随访中,多西环素组首发性传播感染9个月累积概率为22%,低于不预防组的42%,以衣原体和梅毒下降为主,淋病无显著差异。

要点

  • 性行为后24小时内单次口服200mg多西环素可降低MSM首发性传播感染风险。
  • 获益主要来自衣原体和梅毒下降,淋病发病率未见显著下降。
  • 72%的性传播感染无症状,提示定期筛查仍不可替代。

核心结论

  • 在高风险MSM中,多西环素暴露后预防降低了首发细菌性性传播感染的发生。
  • 研究期间未观察到HIV血清转换。

研究设计与样本

  • ANRS IPERGAY试验的开放标签随机子研究,在法国进行。
  • 纳入232名18岁及以上、与男性发生无套性行为并使用替诺福韦二吡呋酯联合恩曲他滨进行HIV暴露前预防的MSM。
  • 按1:1随机分为性行为后24小时内单次口服200mg多西环素组(n=116)与不预防组(n=116)。
  • 主要疗效分析基于意向性治疗人群。

主要发现

  • 102例STI中72例(71%)无症状;严重不良事件发生率两组相似。

关键数值与推荐

  • 多西环素暴露后预防用法:性行为后24小时内单次口服200mg。
  • 多西环素组每月多西环素使用中位数为680mg(IQR 280-1450)。
  • 所有参与者均接受风险降低咨询、安全套并提供定期HIV检测。

临床怎么用

  • 对使用HIV暴露前预防的高风险MSM,可考虑在性行为后24小时内单次口服200mg多西环素以降低衣原体和梅毒风险。
  • 该策略对淋病的预防效果不显著,不应替代安全套使用和定期STI筛查。
  • 因多数STI无症状,实施暴露后预防时仍需维持定期筛查。
  • 需关注胃肠道不良事件,多西环素组报告率53%。

局限性

  • 本研究为开放标签设计,未设盲法。
  • 研究人群为法国使用HIV暴露前预防的MSM,结果外推需谨慎。
  • 淋病终点未观察到显著差异,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased rates of sexually transmitted infections (STIs) have been reported among men who have sex with men. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of STIs. METHODS: All participants attending their scheduled visit in the open-label extension of the ANRS IPERGAY trial in France (men aged 18 years or older having condomless sex with men and using pre-exposure prophylaxis for HIV with tenofovir disoproxil fumarate plus emtricitabine) were eligible for inclusion in this open-label randomised study. Participants were randomly assigned (1:1) at a central site to take a single oral dose of 200 mg doxycycline PEP within 24 h after sex or no prophylaxis. The primary endpoint was the occurrence of a first STI (gonorrhoea, chlamydia, or syphilis) during the 10-month follow-up. The cumulative probability of occurrence of the primary endpoint was estimated in each group with the Kaplan-Meier method and compared with the log-rank test. The primary efficacy analysis was done on the intention-to-treat population, comprising all randomised participants. All participants received risk-reduction counselling and condoms, and were tested regularly for HIV. This trial is registered with ClinicalTrials.gov number, NCT01473472. FINDINGS: Between July 20, 2015, and Jan 21, 2016, we randomly assigned 232 participants (n=116 in the doxycycline PEP group and n=116 in the no-PEP group) who were followed up for a median of 8·7 months (IQR 7·8-9·7). Participants in the PEP group used a median of 680 mg doxycycline per month (IQR 280-1450). 73 participants presented with a new STI during follow-up, 28 in the PEP group (9-month probability 22%, 95% CI 15-32) and 45 in the no-PEP group (42%, 33-53; log-rank test p=0·007). The occurrence of a first STI in participants taking PEP was lower than in those not taking PEP (hazard ratio [HR] 0·53; 95% CI 0·33-0·85; p=0·008). Similar results were observed for the occurrence of a first episode of chlamydia (HR 0·30; 95% CI 0·13-0·70; p=0·006) and of syphilis (0·27; 0·07-0·98; p=0·047); for a first episode of gonorrhoea the results did not differ significantly (HR 0·83; 0·47-1·47; p=0·52). No HIV seroconversion was observed, and 72 (71%) of all 102 STIs were asymptomatic. Rates of serious adverse events were similar in the two study groups. Gastrointestinal adverse events were reported in 62 (53%) participants in the PEP group and 47 (41%) in the no-PEP group (p=0·05). INTERPRETATION: Doxycycline PEP reduced the occurrence of a first episode of bacterial STI in high-risk men who have sex with men. FUNDING: France Recherche Nord & Sud Sida-HIV Hépatites (ANRS) and Bill & Melinda Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2017. PMID: 29229440. doi:10.1016/S1473-3099(17)30725-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。